Key result
Cotreatment with scutellarin significantly protected against doxorubicin-induced acute cardiotoxicity in rats, improving left ventricular ejection fraction from 47.75% to 76.70%.
Why the study?
Does scutellarin prevent doxorubicin-induced acute cardiotoxicity and alter its tissue accumulation in a rat model?
Population
108 male Sprague-Dawley rats (200-250 g weight)
Comparison
Scutellarin 5 mg/kg/day intravenously for 3… vs Doxorubicin alone plus intravenous saline, or…
Design
Preclinical, Rats were randomly divided/assigned into groups…
Follow-up
Up to 72 hours
Authors
Loading...
Scutellarin may attenuate doxorubicin cardiotoxicity in rats; leaves open translation to human prevention.
Does scutellarin prevent doxorubicin-induced acute cardiotoxicity and alter its tissue accumulation in a rat model?
Absolute Event Rate: 76.7% vs 47.75%
p-value: p=<0.05
Scutellarin protects against doxorubicin-induced acute cardiotoxicity in rats by reducing oxidative stress and decreasing doxorubicin accumulation in the heart without altering systemic plasma exposure.
Sun et al. (2017) studied Doxorubicin-induced acute cardiotoxicity (n=108). Scutellarin vs. Doxorubicin alone was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.05). Cotreatment with scutellarin significantly protected against doxorubicin-induced acute cardiotoxicity in rats, improving left ventricular ejection fraction from 47.75% to 76.70%.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: